相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies A retrospective analysis of the LifeLink database
Jennie H. Best et al.
DIABETES CARE (2011)
Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications
Richard M. Bergenstal et al.
AMERICAN JOURNAL OF MEDICINE (2010)
DURATION-1 Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
John B. Buse et al.
DIABETES CARE (2010)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Richard M. Bergenstal et al.
LANCET (2010)
STATEMENT BY AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CONSENSUS PANEL ON TYPE 2 DIABETES MELLITUS: AN ALGORITHM FOR GLYCEMIC CONTROL
Helena W. Rodbard et al.
ENDOCRINE PRACTICE (2009)
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
Kausik K. Ray et al.
LANCET (2009)
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
William Duckworth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
David C. Klonoff et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Total cardiovascular risk management
Eberhard Ritz
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Preventing cardiovascular disease and diabetes - A call to action from the American Diabetes Association and the American Heart Association
Robert H. Eckel et al.
CIRCULATION (2006)
Risk factors for renal dysfunction in type 2 diabetes - UK prospective diabetes study 74
Ravi Retnakaran et al.
DIABETES (2006)
Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes
DM Eddy et al.
ANNALS OF INTERNAL MEDICINE (2005)
Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
E Selvin et al.
ANNALS OF INTERNAL MEDICINE (2004)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
SM Grundy et al.
CIRCULATION (2004)
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
AV Chobanian et al.
HYPERTENSION (2003)
Archimedes - A trial-validated model of diabetes
DM Eddy et al.
DIABETES CARE (2003)
Validation of the archimedes diabetes model
DM Eddy et al.
DIABETES CARE (2003)
分享论文
